Scholar Rock

Scholar Rock

Edit info

  • Founded: 2014
  • Location: Cambridge, MA
  • Employee range: 50 - 200
  • Clinical stage: Clin3
  • Therapy area: Spinal muscular atrophy
  • Drug types: MUS, ONC, HEM
  • Lead product: Apitegromab
  • Funding: $205 stock Jun 2022; $86.3M IPO Jun 2018


scholarrock.com

linkedin.com

job board


Drug notes:

SRK-181 Clin1 immuno-oncology; 2 undisclosed programs RD/Clin0 anemia, fibrosis

About:

Scholar Rock is discovering new medicines that target inactive forms of growth factors to treat disease. Growth factors in their active form are common therapeutic targets, since they are extracellular and drivers of disease. However, many mature, active forms of different growth factors are structurally similar, limiting drug specificity. Scholar Rock is targeting the inactive precursor, or latent, forms of growth factors to regulate their activity in the tissue microenvironment. To identify therapeutics, Scholar Rock is using their proprietary platform to develop antibody drugs that recognise the prodomain of precursor growth factors. Scholar Rock’s lead candidate, Apitegromab, is in Phase 3 clinical trials for patients with Spinal Muscular Atrophy.

Jobs:

Scholar Rock
Associate Director, Information Security and Data ...
Cambridge, MA|3 days ago
Apply
Scholar Rock
Sr. Systems Support & Desktop Engineer
Cambridge, MA|3 days ago
Scholar Rock
Senior Manager, Data Intergrations
Cambridge, MA|9 days ago
Scholar Rock
Vice President, Patient Advocacy
Cambridge, MA|25 days ago
Scholar Rock
Director, Clinical Quality Assurance
Cambridge, MA|32 days ago
Scholar Rock
Sr. Director, National Accounts
Remote|65 days ago
Scholar Rock
Vice President of Sales
Remote|89 days ago
Scholar Rock
Director/Senior Director, EU Regulatory Strategy
Remote|100+ days ago
Scholar Rock
Scientist/Sr. Scientist, Device Engineering- Drug ...
Cambridge, MA|100+ days ago


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com